In 9M FY25 the net profit has been up 85 per cent Y-o-Y to Rs 27.29 crore
Ahmedabad-based Hester Biosciences has reported a consolidated net profit of Rs 11.41 crore in Q3FY25 ended December 2024 as against a net profit of Rs 4.02 crore in Q3FY24, a growth of 184 per cent.
The company reported revenue from operations of Rs 63.22 crore for Q3FY25, a fall of 6 per cent Y-o-Y as compared to revenue from operations of Rs. 66.98 crore in Q3FY24. EBITDA during Q3FY25 ended December 2024 was reported at Rs 13.85 crore, 12 per cent growth Y-o-Y from Rs 12.35 crore in Q3FY24. EPS for Q3FY25 was reported at Rs. 13.41 per share.
Looking ahead, our focus remains on achieving bottom-line targets while driving growth across divisions. The upcoming launch of the Avian Influenza vaccine, scheduled for release this year, is expected to significantly enhance the performance of the Poultry Healthcare Division and create new export opportunities. Additionally, we continue to prioritise the expansion of the Petcare Division, leveraging its strong growth momentum to solidify our market position.
The company reported a net profit of Rs 27.29 crore in 9M FY25 ended December 2024 as against a net profit of Rs 14.77 crore in 9M FY24, a growth of 85 per cent. The company reported revenue from operations of Rs 229.18 crore for the 9M FY25, a growth of 2 per cent Y-o-Y. EBITDA during 9MFY25 ended December 2024 was reported at Rs 55.53 crore, 15 per cent growth Y-o-Y from Rs 48.35 crore in 9M FY24. EPS for 9MFY25 was reported at Rs 32.07 per share.
